Singulair Design Defect Claims Not Automatically Preempted, Calif. Federal Judge Rules

  • Order

SAN FRANCISCO — A California federal judge has ruled that design defect claims asserted against the makers of the asthma drug Singulair are not preempted based upon the facts before the court, because they failed to show it was impossible for them to implement a safer design prior to FDA approval.

In a Nov. 21 order, Judge Jeffrey S. White of the U.S. District Court for the Northern District of California added that defendants may renew their preemption argument on a motion for summary judgment.

Defendants Merck & Co. Inc., Merck Sharp & Dohme Corp., Organon & Co., and Organon …


HarrisMartin's New Jersey Asbestos Litigation Conference

March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick


HarrisMartin's Webinar Series: Suboxone (Buprenorphine/Naloxone) Film Marketing, Sales Practices and Products Litigation - MDL No. 3092

December 18, 2023